+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030- Product Image
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030- Product Image
Sale

Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The multiple myeloma drug market is advancing rapidly as stakeholders adapt to technological innovations, evolving treatment paradigms, and changing global regulatory and economic conditions. Senior decision-makers require focused insight to adjust strategies and capture value in this competitive, regulation-driven environment.

Market Snapshot: Multiple Myeloma Drug Market Overview

The Multiple Myeloma Drug Market grew from USD 24.51 billion in 2024 to USD 26.52 billion in 2025. It is expected to continue growing at a CAGR of 8.07%, reaching USD 39.05 billion by 2030. Market growth is fueled by increasing incidence, breakthrough therapies, and expanded access, with regional differences in adoption and pricing shaping competitive dynamics. Industry leaders are pursuing innovation while navigating complex reimbursement and distribution environments.

Scope & Segmentation

This report provides a detailed analysis of the multiple myeloma drug market, focusing on major segments, product types, and regions.

  • Drug Classes: Histone deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, proteasome inhibitors
  • Therapy Lines: First-line, second-line, third and subsequent therapies
  • Treatment Regimens: Combination therapy approaches including doublet, triplet, and quadruplet regimens, as well as monotherapy
  • Routes of Administration: Intravenous, oral, and subcutaneous treatments
  • Distribution Channels: Hospital, online, and retail pharmacy settings
  • Patient Age Groups: Sixty and above, under sixty
  • Gender Profile: Female and male patients
  • Regional Coverage: Americas (including major US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (across 20 key countries), Asia-Pacific (including China, India, Japan, Australia, and several Southeast Asian markets)
  • Company Landscape: Including profiles of Bristol-Myers Squibb, Janssen Biotech, Takeda Pharmaceuticals, Amgen, Novartis, and other significant market participants

Key Takeaways for Senior Decision-Makers

  • Innovative mechanisms such as monoclonal antibodies and expanded immunomodulatory agents are rapidly shifting standards of care, especially in frontline and relapsed settings.
  • Combination regimens are gaining traction, with quadruplet therapies emerging for higher-risk patients, emphasizing the move toward risk-adapted, personalized care.
  • The rise of oral and subcutaneous formulations is improving patient convenience and adherence, leading to increased outpatient care and shifting the treatment delivery landscape.
  • Regional reimbursement and regulatory structures create varying market opportunities, requiring tailored access, partnering, and pricing strategies across geographies.
  • Digital health platforms and real-world evidence are pivotal for optimizing regimen selection, supporting payer negotiations, and refining commercialization approaches.

Tariff Impact and Strategic Response

In 2025, updated US tariff structures are set to influence input costs, particularly for imported active pharmaceutical ingredients. Manufacturers are exploring price adjustments, vertical integration, and stockpiling to mitigate these pressures. The changes prompt an intensified focus on payer engagement and more robust pharmacoeconomic data to support market access and sustainable pricing. These dynamics encourage deeper collaboration among suppliers, payers, and healthcare providers in the United States.

Methodology & Data Sources

The analysis combines verified secondary sources, such as peer-reviewed literature and proprietary databases, with primary research across oncology stakeholders and payers in key markets. Data reconciliation strategies and regional model calibration underpin reliable forecast and trend validation.

Why This Report Matters

  • Delivers actionable intelligence for senior leaders seeking to realign portfolios and investment in response to evolving therapeutic and economic conditions.
  • Helps teams identify growth opportunities, risk factors, and competitive differentiation strategies based on nuanced segmentation and real-world payer insights.
  • Equips market access, clinical, and commercial leaders to develop resilient strategies attuned to the realities of shifting global reimbursement and supply chains.

Conclusion

This report offers a definitive guide to the complexities and emerging opportunities in the multiple myeloma drug market. Executives are empowered to refine strategies, engage with key market trends, and position their organizations for sustained leadership in a transforming landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Myeloma Drug Market, by Drug Class
8.1. Introduction
8.2. Histone Deacetylase Inhibitors
8.2.1. Panobinostat
8.3. Immunomodulatory Agents
8.3.1. Lenalidomide
8.3.2. Pomalidomide
8.3.3. Thalidomide
8.4. Monoclonal Antibodies
8.4.1. Daratumumab
8.4.2. Elotuzumab
8.4.3. Isatuximab
8.5. Proteasome Inhibitors
8.5.1. Bortezomib
8.5.2. Carfilzomib
8.5.3. Ixazomib
9. Multiple Myeloma Drug Market, by Line of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third and Beyond
10. Multiple Myeloma Drug Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.2.1. Doublet Regimen
10.2.2. Quadruplet Regimen
10.2.3. Triplet Regimen
10.3. Monotherapy
11. Multiple Myeloma Drug Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Multiple Myeloma Drug Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Multiple Myeloma Drug Market, by Patient Age
13.1. Introduction
13.2. Sixty and Above
13.3. Under Sixty
14. Multiple Myeloma Drug Market, by Gender
14.1. Introduction
14.2. Female
14.3. Male
15. Americas Multiple Myeloma Drug Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Multiple Myeloma Drug Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Multiple Myeloma Drug Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Bristol-Myers Squibb Company
18.3.2. Janssen Biotech, Inc.
18.3.3. Takeda Pharmaceutical Company Limited
18.3.4. Amgen Inc.
18.3.5. Novartis International AG
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. MULTIPLE MYELOMA DRUG MARKET MULTI-CURRENCY
FIGURE 2. MULTIPLE MYELOMA DRUG MARKET MULTI-LANGUAGE
FIGURE 3. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 79. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 80. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 82. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 83. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 84. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 87. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 95. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 155. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 156. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 161. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 165. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 168. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 169. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 185. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 188. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 191. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 192. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 193. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 196. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 204. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 251. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 252. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 253. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 269. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 272. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 273. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 275. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 276. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 277. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 280. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 281. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 287. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 288. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 289. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 292. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 317. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 319. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Multiple Myeloma Drug market report include:
  • Bristol-Myers Squibb Company
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis International AG

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 39.05 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030 - Product Image

Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032 - Product Image

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2025 - Product Image

Multiple Myeloma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Multiple Myeloma Therapeutics - Global Strategic Business Report - Product Image

Multiple Myeloma Therapeutics - Global Strategic Business Report

  • Report
  • 293 Pages
  • Global
From

About the Multiple Myeloma Drug Market

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.